CLINICAL TRIALS PROFILE FOR TRIAZOLAM

All Clinical Trials for triazolam

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00671632 ↗	Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse	Completed	Takeda	Phase 2	2003-06-01	The purpose of this study is to determine the relative abuse potential of ramelteon, once daily (QD), compared to triazolam in subjects with a history of drug abuse.
NCT00695630 ↗	Flumazenil Reversal of Oral Triazolam	Completed	National Institutes of Health (NIH)	Phase 1/Phase 2	2006-09-01	An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes).
NCT00695630 ↗	Flumazenil Reversal of Oral Triazolam	Completed	University of Washington	Phase 1/Phase 2	2006-09-01	An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes).

Clinical Trial Conditions for triazolam

Condition Name

Condition Name for triazolam
Intervention	Trials
Healthy	4
Sedation	2
Anxiety	2

Condition MeSH

Condition MeSH for triazolam
Intervention	Trials
Anxiety Disorders	2
Postoperative Complications	1
Hemorrhage	1

Clinical Trial Locations for triazolam

Trials by Country

Trials by Country for triazolam
Location	Trials
United States	9
Belgium	2
Taiwan	2
United Kingdom	1
Lebanon	1

Trials by US State

Trials by US State for triazolam
Location	Trials
Pennsylvania	1
Massachusetts	1
Texas	1
Georgia	1
Florida	1

Clinical Trial Progress for triazolam

Clinical Trial Phase

Clinical Trial Phase for triazolam
Clinical Trial Phase	Trials
PHASE4	2
PHASE1	1
Phase 4	5

Clinical Trial Status

Clinical Trial Status for triazolam
Clinical Trial Phase	Trials
Completed	14
Not yet recruiting	3
RECRUITING	2

Clinical Trial Sponsors for triazolam

Sponsor Name

Sponsor Name for triazolam
Sponsor	Trials
Pfizer	3
National Taiwan University Hospital	2
AcelRx Pharmaceuticals, Inc.	1

Sponsor Type

Sponsor Type for triazolam
Sponsor	Trials
Other	28
Industry	9
NIH	1

Last updated: April 28, 2026

Triazolam: Clinical Trials Update, Market Analysis, and Projection

What is the current clinical trial status for triazolam?

No complete, current, trial-level dataset is available in the provided inputs, and a comprehensive status call would be speculative.

What is the commercial context and where does triazolam sit in the market?

Triazolam is a benzodiazepine hypnotic used for short-term management of insomnia in multiple jurisdictions historically, with regulatory and commercial standing shaped by:

• Short-course treatment positioning typical of sedative-hypnotics.
• Generic competition across many established benzodiazepines, which typically compresses unit pricing and lowers revenue concentration to the originator only in limited geographies.
• Safety and labeling constraints common to benzodiazepine class products (sedation, dependence, misuse risk), which influence payer coverage and prescribing patterns.

Market activity for triazolam has historically tracked the broader benzodiazepine hypnotic segment, which has migrated over time toward:

• Shorter-acting hypnotics in some markets (including non-benzodiazepine hypnotics).
• Preference for agents with different safety and dependence profiles in formulary decisions.

How is triazolam likely to perform under market structure and competitive forces?

Across established benzodiazepine hypnotics, the dominant determinants of performance are usually:

• Generic penetration and formulary substitution
• Availability and contract pricing in pharmacy channels
• Regional regulatory stance on benzos for insomnia
• Shift of prescribers toward alternative insomnia classes

For triazolam specifically, the practical implication for projection is that revenue is usually not driven by high-growth share gains but by:

• Remaining branded pockets where generics are delayed or where brand persistence exists.
• Low-competition niches where specific dosing formulations or physician familiarity supports continued demand.
• Persistent baseline demand consistent with insomnia treatment continuity.

What are the market projections for triazolam (base-case framework)?

A defensible numerical projection requires current sales and pricing intelligence, which is not present in the provided inputs. Without those inputs, producing a quantified forecast would not be accurate.

What could change triazolam’s outlook over the next cycle?

The near-term outlook typically hinges on policy and lifecycle events such as:

• Patent expiry and generic entry timing in key countries (if applicable).
• Formulary restrictions for benzodiazepines or specific hypnotic subsets.
• Class-wide prescribing constraints following safety communications.
• Reformulations that affect market access (e.g., packaging, dosing strengths, or regulatory updates).

Key Takeaways

• A complete, current clinical trial update cannot be produced from the information provided.
• Triazolam’s market performance is structurally constrained by the benzodiazepine hypnotic lifecycle, generic penetration patterns, and formulary/policy dynamics.
• A quantified forecast for market size and revenue cannot be produced accurately without current market data and trial-level intelligence.
• Outlook drivers are mostly external: generic entry timing, formulary policy, and regulatory labeling constraints.

FAQs

1. Is triazolam still actively studied in clinical trials?
   A current trial status update requires access to a live trial registry dataset; it is not available in the provided inputs.

2. How does generic competition typically affect triazolam revenue?
   It usually compresses pricing and reduces branded revenue to smaller geographies or niches where brand persistence exists.

3. What determines formulary access for benzodiazepine hypnotics like triazolam?
   Safety labeling, dependence/misuse risk controls, and restrictions on duration of use and patient populations.

4. Do insomnia competitors (non-benzodiazepine hypnotics) substitute for triazolam?
   In many markets, yes, especially where prescribers and payers prefer alternative hypnotic classes.

5. What events most often change the demand trajectory for established hypnotics?
   Patent/generic lifecycle milestones, safety communications, and formulary policy shifts.

---

References

[1] FDA. Drug Safety Communication(s) for benzodiazepines and Z-drugs (class-related safety communications). (FDA website).
[2] EMA. Assessment/communications relating to benzodiazepines for sedation and insomnia (class-related regulatory materials). (EMA website).
[3] WHO. Benzodiazepines (class pharmacology and risk context) (WHO resources). (WHO website).